Voy­ager co-founder Steven Paul steps down from CEO seat; Al­ny­lam en­ters fi­nal stretch at the FDA with patisir­an

Voy­ager Ther­a­peu­tics $VY­GR is hunt­ing for a new CEO as co-founder and cur­rent chief ex­ec­u­tive Steven Paul has de­cid­ed to fo­cus on pre­clin­i­cal dis­cov­ery re­search and port­fo­lio de­vel­op­ment. Af­ter six years on the front line, he will tran­si­tion to the role of ex­ec­u­tive sci­ence ad­vi­sor and stay on both the board and the sci­ence & tech com­mit­tee. Paul, an Eli Lil­ly vet, was a ven­ture part­ner at Third Rock when he helped form the biotech, known for its gene ther­a­py for Parkin­son’s dis­ease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.